Asthma and bipolar disorder (BD) are 2 distinct diseases that share similar pathophysiology. This study aimed to determine their relationship thorough a meta-analysis of articles on their comorbidity rate.

The aim of the study is to examine the overall prevalence rate of BD in asthmatic patients and of asthma in BD patients compared to healthy controls.

Electronic research of PubMed and ClinicalTrials.gov was performed. Manuscripts discussing the prevalence rate of BD in patients with/without asthma and the prevalence rate of asthma in those with/without BD, as well as clinical trials in humans and case-controlled trials or cohort studies, were all included. Case reports or series and nonclinical trials were excluded.

Through a random-effects model, a meta-analysis of the results of 4 studies comparing the prevalence rate of BD in patients with/without asthma, and in 6 studies comparing the prevalence rate of asthma in subjects with/without BD were performed.

There were significantly higher prevalence rates of BD in asthmatic patients than in healthy controls ($P < 0.001$) and of asthma in BD patients than in healthy controls ($P < 0.001$). Only the patient’s mean age significantly modulated the odds ratio of the prevalence rate of asthma in BD patients ($\text{slope} = 0.015, P < 0.001$).

Only 10 studies were included and most were cross-sectional studies. The possible confounding effect of medication on BD or asthma onset was not investigated. Any possible etiology of the comorbidity was also not determined.

This meta-analysis highlights the importance of the significantly high comorbid rate of BD and asthma, and the positive association with age. Special attention must be given to the comorbidity of asthma and BD, especially in older patients.

**INTRODUCTION**

Asthma is a troublesome disease that has a high mortality rate in the world. Similarly, bipolar disorder (BD) contributes to significant socio-economic burden globally. These 2 belong to distinct disease categories and do not seem to have any association with each other. However, as knowledge on the comorbidity of BD improves, many more comorbid illnesses have been found. In recent reports, asthma has been associated with BD. This is especially important as patients with severe mental illness are believed to have higher comorbidities and higher mortality rates compared to healthy subjects. These patients also have less healthy habits and less medical consults. Thus, public health policies must be drawn up to address these problems.

Asthma has been initially believed to be a disorder of inflammation. In asthmatic patients, inflammatory cytokines like interleukin-4 (IL-4), IL-5, and IL-13 are altered along with asthma exacerbation. Similarly, BD patients are found to have dysfunction of inflammation when the disease is aggravated or subsides. Alterations of IL-4, IL-6, and IL-12 have been proven in BD patients under different emotional states. As such, some researchers suggest that these 2 diseases at least share similar mechanisms in their pathophysiology.

Moreover, in clinical practice, some reports discuss the comorbidity of asthma and BD, either in forms of first onset of asthma or BD. Some have tried to investigate the prevalence...
rate of asthma in BD patients compared to healthy controls.11–17 On the other hand, other studies have compared the prevalence rate of BD in asthmatic patients and in healthy controls.10,18–20 Lastly, the medication used in 1 disease may cause a flare up of the other disease. For example, the steroids used in asthma may aggravate the emotional changes in BD.21

In clinical studies, there is a significantly higher prevalence rate of asthma in BD patients11,13–17 or a significantly higher prevalence rate of BD in asthmatic patients compared to those in health controls.10,18,20 However, in another report, there is no significant association between asthma and BD.12,19 Such inconsistency may be due to different study designs,19,20 different latitudes and hemispheres,12,14 or different sex proportion.10,19 These findings have implications on clinical practice and public health policy.

The present study aimed to summarize current evidences on the comorbidity rate of asthma and BD through meta-analysis and to investigate any possible association between comorbidity and clinical variables in such patients.

METHODS AND MATERIALS

Literature Search and Screening

A previous meta-analysis protocol was followed for the present research strategy.22 In the first stage, the identification stage, 2 independent psychiatrists performed a systematic literature search with the electronic database of PubMed and ClinicalTrials.gov. To include as many studies as possible, the most simple keywords of “(asthma) AND (bipolar)” was used in the search process, which was limited to only articles written in English and was conducted on December 29, 2015. The 2 authors then examined the titles and abstracts in the screening stage. Reports that were not related to the prevalence rate of BD and asthma were excluded. Inconsistencies and disagreements in selection were settled through consensus after reading the full text of these studies.

Later, in the stage of eligibility, the remaining studies were re-screened using the inclusion criteria of: (1) articles discussing the prevalence rate of BD in subjects with/without asthma or articles discussing the prevalence rate of asthma in subjects with/without BD; (2) articles on clinical trials in humans; and (3) case-controlled trials or cohort studies. Case reports or series, and nonclinical trials were excluded.

The meta-analysis was divided into 2 parts. The first part was a meta-analysis of articles discussing the prevalence rate of BD in patients with/without asthma. The second was a meta-analysis of articles discussing the prevalence rate of asthma in subjects with/without BD. The primary outcomes were the prevalence rate of BD in patients with/without asthma and the prevalence rate of asthma in patients with/without BD.

All primary outcomes and clinical variables in the studies were extracted as much as possible. If the data were not available, the authors were contacted for the original data. The entire screening and selection process was shown in Figure 1.

Meta-Analysis and Data Extraction

In the current meta-analysis, the effect size (ES), set as the standardized mean difference based on the odds ratio and treated with a random effects model, was defined as the difference in the prevalence rate of BD in patients with/without asthma and of asthma in subjects with/without BD. An ES > 0 was defined as “favor comorbidity.” If there were no actual case numbers or prevalence rates, or no response from the authors, other statistical parameters such as the t or P value with the sample size was used to calculate the ES.

The meta-analysis procedures were performed via the platform of the Comprehensive Meta-Analysis software, version 2 (Biostat, Englewood, NJ). Statistical significance was set
at a 2-tailed \( P < 0.05 \). Through Q statistics, related \( P \) values, and \( F \) statistics, heterogeneity in the included studies was investigated. At the same time, publication bias was investigated by visual examination of funnel plots and through Egger’s regression analysis.  

To evaluate the possible confounding effects of clinical variables, subgroup meta-analysis and meta-regression were performed. The meta-regression was performed through the unrestricted maximum likelihood method. The extracted clinical variables for meta-regression included research duration (period of study), mean age, sex proportion (female), age of onset, and race proportion (i.e., African American, Caucasian, Asian, and Native American). The meta-analysis used here fulfilled the criteria of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) (Supplement Table 1 and Supplement Figure 1, http://links.lww.com/MD/A884). Besides, the ethical approval was not applicable in current study because we would not deal with the patients’ personal data. Furthermore, there were no any patients being harmed due to any procedure in the present study.

**RESULTS**

**Studies Included in Each Meta-Analysis**

Thirteen articles were initially eligible, but one did not have a control group and one contained not simply BD patients. Of the remaining 11 articles, 2 were conducted by the same research team and their clinical data were the same. Thus, only 1 was used to avoid unnecessary duplication. Ten articles were finally included in the meta-analysis (Table 1), including 4 on the prevalence rate of BD in patients with/without asthma and 6 on the prevalence rate of asthma in patients with/without BD.

**Meta-Analysis of the Prevalence Rate of BD in Patients With/Without Asthma**

This meta-analysis of 4 studies included 50,358 patients with asthma and 109,218 healthy controls. The prevalence rate of BD was significantly higher in asthmatic patients than in healthy controls (ES: 2.12; 95% confidence interval [CI]: 1.57–2.87; \( P < 0.001 \)) (Figure 2A). There was no statistically significant heterogeneity within the recruited studies (\( Q = 5.36; df = 3; I^2 = 44.05\%; P = 0.147 \)). There was also no statistically significant publication bias detected by Egger’s test (\( t = 0.79; df = 2; 2\)-tailed \( P = 0.514 \)) or by visual examination of the funnel plot.

Meta-regression was only performed for the female proportion because of the lack of data. There was no statistically significant association between the prevalence rate of BD in patients with asthma and female sex (\( P = 0.953 \)).

**Meta-Analysis of the Prevalence Rate of Asthma in Patients With/Without BD**

Six studies that covered 5750 patients with BD and 139,529 healthy controls were included in this meta-analysis. There was a significantly higher prevalence rate of asthma in patients with BD than that in healthy controls (ES: 1.86; 95% CI: 1.40–2.47; \( P < 0.001 \)) (Figure 2B). However, there was statistically significant heterogeneity within the recruited studies (\( Q = 59.88; df = 5; F = 91.65\%; P < 0.001 \)). There was no significant publication bias by Egger’s test (\( t = 0.31; df = 4; 2\)-tailed \( P = 0.776 \)) or by visual examination of the funnel plot.

In the meta-regression, there was a significantly positive association between the odds ratio of asthma in patients with BD and mean age (slope: 0.015; \( P < 0.001 \)) rather than female sex proportion or the proportions of Caucasian, Asian, and Native American (\( P = 0.737, 0.797, 0.807, \) and 0.786, respectively). A meta-regression of African American and duration of research was not performed because of the lack of data.

**DISCUSSION**

The current meta-analysis demonstrates that BD and asthma have a significant comorbidity rate with each other. The prevalence rate of asthma is significantly higher in BD patients than in healthy controls. Similarly, the prevalence rate of BD is significantly higher in asthmatic patients than in healthy controls. Among the clinical variables, only mean age has a significantly positive association with the odds ratio of asthma in BD patients.

This meta-analysis provides evidences of the significantly high prevalence rate of comorbid of asthma and BD. In previous reports, evidences reveal that both asthma and BD share common immune abnormalities, such as the abnormal expressions of IL-6,7,8,27,28 and tumor necrosis factor-\( \alpha \) (TNF-\( \alpha \)).21,30 The high comorbidity between these 2 distinct diseases should be important for clinicians but in clinical practice, there remains a paucity of conclusive evidence as regards the comorbid prevalence rates. This meta-analysis provides the link between these 2 distinct diseases in clinical application, which is especially important because in clinical practice, the physical problems are frequently missed in patients with severe mental illness. Thus, psychiatrists should be aware of possible comorbid asthma during the treatment of BD. Medication with exacerbating effects on the asthmatic activity, such as beta-blocker, must be avoided. At the same time, physicians should pay attention to distinguishing the symptoms of asthma and agitation during manic attack and avoid medications, such as steroids, that can induce manic symptoms.21,30

Although there is no statistically significant publication bias detected in the present study, most patients are either in countries located at higher latitudes or in the Northern Hemisphere or mainly in a few countries such as Taiwan10,18,19 and the United States.11,15 This may be because the health care system is widely-used and is well-established in these areas.

However, this imbalance in the distribution of countries of the studies may result in some publication bias in the current meta-analysis. The distribution and frequency of asthma vary with climate and air pollution in the environment. Although there is no statistically significant publication bias in the current meta-analysis, the distribution and frequency of asthma are likely to be higher in countries located at higher latitudes or in the Northern Hemisphere or mainly in a few countries such as Taiwan and the United States. This may be because the health care system is widely-used and is well-established in these areas.

An interesting finding is the significantly positive association between mean age and the odds ratio of asthma in patients with BD. In previous reports, asthma is believed to be more severe in older than in younger patients and that there is a higher mortality rate in patients >50 years old. Moreover, the older the age of asthma onset, the more frequent the steroid treatment is needed. This phenomenon may be explained by trends in the alteration of specific immune cytokines, such as the reduction in interferon-gamma (IFN-\( \gamma \)) along with aging, which has been correlated with asthma severity. At the same time, there are changes in specific immune cytokines in patients with BD, such as reduced IFN-\( \gamma \) and increased IL-4 and TNF-\( \alpha \). At present, there are no reports that provide a correlation between immunity and the age of patients with BD.

Further investigations on the association between age of immunity dysfunction and onset of asthma are therefore warranted in the future.
| Study                        | Comparison | Subjects     | N     | Prevalence Rate (%) | Gender (%) Female | Mean Age (y) | Race (Africa America) | Race (White) | Race (Asian) | Race (Native America) | Age of Onset | Country            |
|-----------------------------|------------|--------------|-------|---------------------|-------------------|--------------|------------------------|--------------|--------------|------------------------|--------------|--------------------|
| Alonso et al (2014)        | Asthma     | Asthma       | 1860  | 3.2                 | n/a               | n/a          | n/a                    | n/a          | n/a          | n/a                    | n/a          | Global             |
| Chen et al (2014)$^a$       | Asthma     | Control group| 49296 | 1.8                 | 1.0               | 41.8         | 11.7 ± 1.6             | n/a          | n/a          | n/a                    | 18.9 ± 2.7   | Taiwan             |
| Chen et al (2014)$^a$       | Control group| Asthma      | 1453  | 1.0                 | 41.8              | 11.7 ± 1.6   | n/a                    | n/a          | n/a          | n/a                    | 15.5         | Taiwan             |
| Chen et al (2014)$^a$       | Asthma     | Control group| 5812  | 0.3                 | 39.7              | 11.8 ± 1.6   | n/a                    | n/a          | n/a          | n/a                    | 15.5         | Taiwan             |
| Lin et al (2014)$^a$        | Asthma     | Control group| 46558 | 0.3                 | 47.5              | 11.7 ± 1.7   | n/a                    | n/a          | n/a          | n/a                    | n/a          | Taiwan             |
| Schoepf and Heun (2014)     | Bipolar    | Control group| 46558 | 0.1                 | 47.5              | 47.3 ± 0.7   | n/a                    | 72.0         | 8.2          | 5.0                    | n/a          | Germany            |
| Mitchell et al (2013)$^a$   | Bipolar    | Control group| 621   | 14.5                | 58.9              | 47.3 ± 0.7   | n/a                    | 72.0         | 8.2          | 5.0                    | n/a          | Australia          |
| Castilla-Puentes et al (2011)$^a$ | Bipolar disorder | 8320  | 8.3       | 59.0               | 35.8 ± 10.1     | 2.1          | 85.3                   | 1.0          | 2.0          | n/a                    | Mid and South America |
| Jerrell et al (2010)$^a$    | Bipolar    | Control group| 1427  | 9.0                 | 52.0              | 36.6 ± 11.2  | n/a                    | 27.2         | 9.0          | n/a                    | USA          | USA                |
| McIntyre et al (2006)$^a$   | Bipolar    | Control group| 938   | 15.9                | n/a               | 7.3 ± 3.5    | n/a                    | n/a          | n/a          | n/a                    | Canada        | USA                |
| Hirschfeld et al (2003)$^a$ | Bipolar    | Control group| 2134  | 18.3                | 64.3              | n/a          | 6.3                    | 87.9         | 0.8          | 0.6                    | n/a          | USA                |

Data presentation: mean ± SD.
BD = bipolar disorder, n/a = not available, SD = standard deviation, USA = United States.
$^a$The comparison of prevalence of BD in subjects with/without asthma.
$^b$The comparison of prevalence of asthma in subjects with/without BD.
LIMITATIONS

This study has some limitations that must be considered. First, the total number of studies included is small, especially in the meta-analysis of the prevalence rate of BD in patients with/without asthma, which may influence the meta-analysis. Second, most of the included studies are cross-sectional studies. In fact, mean age, when available, has a wide range in each study. The mean ages of BD and asthma onset are distinct. This may result in the under-diagnosis of such diseases. Third, the possible confounding effects of medication on the onset of BD or asthma are not investigated. As previously mentioned, some medications such as beta-blockers or steroids can result in symptoms of asthma or mood changes. Furthermore, although there was an attempt to extract most of the clinical variables, the related meta-regression was not performed because of the lack of data. Lastly, only a conclusion of “observation result” was attained in the present study. We could only prove the “comorbidity” rather than “same etiology/pathophysiology.” Therefore, the phenomenon of comorbidity might be derived from similar risk factors or symptomatology, such as anxiety, but not from the same etiology or pathophysiology between these 2 diseases. We lack of the “key” link between these 2 diseases. Therefore, clinicians need to be careful when apply our study in clinical practice.

CONCLUSION

The current meta-analysis highlights the importance of the significantly high comorbid rate of BD and asthma, and the positive association with age. These findings serve to remind clinicians that special attention should be given to the comorbidity of asthma and BD, especially in older patients.

REFERENCES

1. Fernandes AG, Souza-Machado C, Coelho RC, et al. Risk factors for death in patients with severe asthma. J Bras Pneumol. 2014;40:364–372.
2. Vreeland B. Bridging the gap between mental and physical health: a multidisciplinary approach. J Clin Psychiatry. 2007;68(Suppl 4):26–33.
3. Deshpande DA, Dileepan M, Walseth TF, et al. MicroRNA regulation of airway inflammation and airway smooth muscle function: relevance to asthma. Drug Dev Res. 2015;76:286–295.
4. Dunican EM, Fahy JV. The Role of type 2 inflammation in the pathogenesis of asthma exacerbations. Ann Am Thorac Soc. 2015;12(Suppl 2):S144–S149.
5. Goldstein BI, Lotrich F, Axelson DA, et al. Inflammatory markers among adolescents and young adults with bipolar spectrum disorders. J Clin Psychiatry. 2015;76:1556–1563.
6. Su KP, Leu SJ, Yang YY, et al. Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission. J Affect Disord. 2002;71:205–209.
7. Kauer-Sant’Anna M, Kapczinski F, Andradeza AC, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009;12:447–458.
8. Brietzke E, Stertz L, Fernandes BS, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116:214–217.
9. Kim YK, Suh IB, Kim H, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry. 2002;7:1107–1114.
10. Lin TC, Lee CT, Lai TJ, et al. Association of asthma and bipolar disorder: a nationwide population-based study in Taiwan. J Affect Disord. 2014;168:30–36.
11. Jerrell JM, McIntyre RS, Tripathi A, et al. A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychiatry. 2010;71:1518–1525.
12. Mitchell PB, Johnston AK, Frankland A, et al. Bipolar disorder in a national survey using the World Mental Health Version of the Composite International Diagnostic Interview: the impact of differing diagnostic algorithms. Acta Psychiatr Scand. 2013;127:381–393.
13. Jerrell JM, McIntyre RS, Tripathi A, et al. Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder. *Hum Psychopharmacol.* 2011;26:451–459.

14. McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. *Psychiatr Serv.* 2006;57:1140–1144.

15. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. *J Clin Psychiatry.* 2003;64:53–59.

16. Schoepf D, Heun R. Bipolar disorder and comorbidity: increased prevalence and increased relevance of comorbidity for hospital-based mortality during a 12.5-year observation period in general hospital admissions. *J Affect Disord.* 2014;169:170–178.

17. Castilla-Puentes R, Secin R, Grau A, et al. A multicenter study of bipolar disorder among emergency department patients in Latin-American countries. *Int J Psychiatry Med.* 2011;42:49–67.

18. Chen MH, Su TP, Chen YS, et al. Higher risk of developing major depression and bipolar disorder in later life among adolescents with asthma: a nationwide prospective study. *J Psychiatr Res.* 2014;49:25–30.

19. Chen MH, Su TP, Chen YS, et al. Higher risk of mood disorders among adolescents with ADHD and asthma: a nationwide prospective study. *J Affect Disord.* 2014;156:232–235.

20. Alonso J, de Jonge P, Lim CC, et al. Association between mental disorders and subsequent adult onset asthma. *J Psychiatr Res.* 2014;59:179–188.

21. Brown ES, Suppes T, Khan DA, et al. Mood changes during prednisone bursts in outpatients with asthma. *J Clin Psychopharmacol.* 2002;22:55–61.

22. Tseng PT, Chen YW, Yeh PY, et al. Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA. *Medicine (Baltimore).* 2015;94:e1967.

23. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ.* 1997;315:629–634.

24. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol.* 2009;62:e1–e34.

25. Perugi G, Quanrant G, Belletti S, et al. General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune-allergic diseases. *J Affect Disord.* 2015;170:95–103.

26. Davydow DS, Ribe AR, Pedersen HS, et al. Serious mental illness and risk for hospitalizations and rehospitalizations for ambulatory care-sensitive conditions in Denmark: a nationwide population-based cohort study. *Med Care.* 2016;54:90–97.

27. Li F, Xie X, Li S, et al. Interleukin-6 gene-174G/C polymorphism and bronchial asthma risk: a meta-analysis. *Int J Clin Exp Med.* 2015;8:12601–12608.

28. Daneshmandi S, Pourfathollah AA, Pourpak Z, et al. Cytokine gene polymorphism and asthma susceptibility, progress and control level. *Med Biol Rep.* 2012;39:1845–1853.

29. Patakas D, Argiropoulou V, Louridas G, et al. Beta-blockers in bronchial asthma: effect of propranolol and pindolol on large and small airways. *Thorax.* 1983;38:108–112.

30. Brown ES, Khan DA, Nejtek VA. The psychiatric side effects of corticosteroids. *Ann Allergy Asthma Immunol.* 1999;83 (6 Pt 1):495–503 quiz –4.

31. D’Amato G, Holgate ST, Pawankar R, et al. Meteorological conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the World Allergy Organization. *World Allergy Organ J.* 2015;8:25.

32. von Bulow A, Kriegbaum M, Backer V, et al. The prevalence of severe asthma and low asthma control among Danish adults. *J Allergy Clin Immunol Pract.* 2014;2:759–767.

33. Kuhlen JL Jr, Wahlquist AE, Nietert PJ, et al. Identification of asthma phenotypes in a tertiary care medical center. *Am J Med Sci.* 2014;348:480–485.

34. Davoodi P, Mahesh PA, Holla AP, et al. Serum levels of interleukin-13 and interferon-gamma from adult patients with asthma in Mysore. *Cytokine.* 2012;60:431–437.

35. Smart JM, Horak E, Kemp AS, et al. Polyclonal and allergen-induced cytokine responses in adults with asthma: resolution of asthma is associated with normalization of IFN-gamma responses. *J Allergy Clin Immunol.* 2002;110:450–456.

36. Leonard C, Tormey V, Burke C, et al. Allergen-induced cytokine production in atopic disease and its relationship to disease severity. *Am J Respir Cell Mol Biol.* 1997;17:368–375.

37. Guloksuz S, Cetin EA, Cetin T, et al. Cytokine levels in euthymic bipolar patients. *J Affect Disord.* 2010;126:458–462.